Clinical trials: Prostate Cancer, Castration Resistant
Metastatic Castration-resistant Prostate Cancer, Bone Metastases
A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
This is an observational study in which data from Chinese men with metastatic castration-resistant prostate cancer that has spread to the bones and who start Radium-223 therapy is studied.
- Trial name
- CREDIT (NCT05301062)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Bayer
Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 9 years.
- Trial name
- NCT01517802
- Testing
- Abiraterone acetate, Prednisone
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 32 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms, Castration-Resistant
A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
The aim of this non interventional study is to describe the proportion of Belgian mCRPC patients which were treated with 1 to 4 and 5 to 6 Radium-223 injections and the patient characteristics which are potentially associated…
- Trial name
- BELFIGO (NCT03563014)
- Testing
- Radium-223 (Xofigo, Bay88-8223)
- Where
- Belgium
- Volunteers
- 164 people
- Sponsor
- Bayer
Prostate Cancer
Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data
We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated machine vision based image analysis of…
- Trial name
- NCT00578409
- Where
- United States
- Volunteers
- 758 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hormone Refractory Prostate Cancer
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer
The aim of this study is to evaluate efficacy and safety of Dovitinib(TKI258) in patients with castration resistant prostate cancer after failure of docetaxel-based chemotherapy.
- Trial name
- NCT01741116
- Testing
- TKI258
- Where
- 2 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- Korean Cancer Study Group
Prostate Cancer
TKI258 in Castrate Resistant Prostate Cancer
The goal of this clinical research study is to learn if a decrease in the levels of prostate specific antigen (PSA) may be linked with the status of prostate cancer that has spread to the bones.
- Trial name
- NCT00831792
- Testing
- TK1258
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer Metastatic Castration-Resistant
External Beam and Radioligand Radiotherapy for mCRPC
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with Lutetium-177 (¹⁷⁷Lu-PSMA) is an established treatment for metastatic prostate cancer.
- Trial name
- ARREST (NCT07354594)
- Testing
- External Beam Radiotherapy Delivered Between Cycles of Radioligand Radiotherapy, Standard of care 177Lutetium-PSMA
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Prostatic Neoplasms
Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting
The purpose of this study is to investigate the prevalence of tissue homologous recombination repair (HRR)-related gene mutations (positive/negative/Variant of uncertain significance (VUS)), clinical outcome such as…
- Trial name
- ZENSHIN (NCT04425200)
- Where
- 26 sites in Japan
- Volunteers
- 205 people
- Sponsor
- AstraZeneca
Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone
Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO)
Metastatic castration resistant prostate cancer causes approximately 258400 deaths annually worldwide. In the presence of metastatic disease, systemic treatment remains the main clinical option.
- Trial name
- ARTO (NCT03449719)
- Testing
- SBRT - Ablative radiation Therapy, Abiraterone Acetate
- Volunteers
- 174 people
- Sponsor
- Lorenzo Livi
Prostate Cancer, Castrate Resistant Prostate Cancer
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib…
- Conditions
- Prostate Cancer, Castrate Resistant Prostate Cancer, BRCA Mutation
- Trial name
- COROS (NCT06783127)
- Testing
- Olaparib
- Where
- 2 sites in Italy
- Volunteers
- 3,000 people
- Sponsor
- Santa Chiara Hospital
Prostatic Neoplasms, Castration-Resistant, Prostate Cancer
A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer
The proposed study will assess the feasibility of an exercise and dietary intervention in men with castrate resistant prostate cancer with secondary outcomes assessing improvements in physical functioning, fatigue, quality of…
- Trial name
- COMRADE (NCT03017417)
- Testing
- Exercise Intervention, standard of care
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Metastatic Castration Resistant Prostate Cancer
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the effectiveness of enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) in the clinical practice setting as measured by time to treatment failure defined…
- Trial name
- PREMISE (NCT02495974)
- Testing
- enzalutamide
- Where
- 182 sites in Austria, Belgium and 14 more
- Volunteers
- 1,763 people
- Sponsor
- Astellas Pharma Europe Ltd.
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Cannabidiol for Pain Relief of Patients With End-stage mCRPC
The goal of this clinical trial is to evaluate the effects of cannabidiol in patients with end-stage metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- ProCan (NCT07549256)
- Testing
- Cannabidiol
- Where
- Denmark
- Volunteers
- 58 people
- Sponsor
- Regionshospital Nordjylland
Castrate Resistance Prostate Cancer
Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer
This is a single site, prospective, Phase 1 pilot trial intended to evaluate the safety and tolerability of adding one IV dose of Desmopressin to CRPC subjects at least 30 minutes prior to commencing standard IV Docetaxel…
- Trial name
- NCT04113005
- Testing
- Desmopressin
- Volunteers
- 10 people
- Sponsor
- Sunnybrook Health Sciences Centre
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Metastatic Castration-Resistant Prostate Cancer
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to investigate radiographic progression-free survival (PFS) of enzalutamide in chemotherapy-naïve patients with progressive metastatic castration-resistant prostate cancer who have symptomatic disease.
- Trial name
- NCT01663415
- Testing
- Enzalutamide
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole
This research trial studies biomarkers in bone marrow and blood samples from patients with prostate cancer treated with ketoconazole.
- Trial name
- NCT01275651
- Testing
- laboratory biomarker analysis
- Where
- United States
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostatic Neoplasms, Castration-Resistant
Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.
The objectives of the study are to analyze the results obtained in survival, safety and quality of life after the combination of SBRT plus second-generation antiandrogen in patients diagnosed with metastatic castration-resistant…
- Trial name
- OLIGORESIST (NCT07717268)
- Testing
- Xtandi, Zytiga® (Abiraterone Acetate), SBRT
- Where
- 15 sites in Spain
- Volunteers
- 51 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Prostate Cancer, Castration-resistant Prostate Cancer
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer
The purpose of this study is to describe patterns in disease management and to describe clinical outcomes, as well as to identify factors influencing physician treatment decisions including reason(s) for treatment choices and…
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
- Trial name
- ASPIRE-PCa (NCT02066961)
- Where
- 93 sites in Algeria, Argentina and 25 more
- Volunteers
- 1,533 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Castration-resistant Prostate Cancer
Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma
This is a prospective observational study on a cohort of patients with castration-resistant prostate cancer M0, treated with Apalutamide, at the Oncology Unit of the "Andrea Tortora" Hospital of Pagani.
- Trial name
- Apa-CARDIO1 (NCT04567875)
- Testing
- No Intervention on patients
- Where
- 2 sites in Italy
- Volunteers
- 54 people
- Sponsor
- Ospedale Andrea Tortora di Pagani